메뉴 건너뛰기




Volumn 58, Issue 20, 2015, Pages 8128-8140

Optimization of a Novel Binding Motif to (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic Acid (AZD9496), a Potent and Orally Bioavailable Selective Estrogen Receptor Downregulator and Antagonist

Author keywords

[No Author keywords available]

Indexed keywords

3 [3,5 DIFLUORO 4 [2 (2 FLUORO 2 METHYLPROPYL) 3 METHYL 2,3,4,9 TETRAHYDRO 1H PYRIDO[3,4 B]INDOL 1 YL]PHENYL]ACRYLIC ACID; ESTROGEN RECEPTOR ANTAGONIST; FULVESTRANT; UNCLASSIFIED DRUG; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AZD9496; CINNAMIC ACID DERIVATIVE; INDOLE DERIVATIVE; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

EID: 84945381593     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b00984     Document Type: Article
Times cited : (149)

References (50)
  • 1
    • 0037364074 scopus 로고    scopus 로고
    • Tamoxifen: a most unlikely pioneering medicine
    • Jordan, V. C. Tamoxifen: a most unlikely pioneering medicine Nat. Rev. Drug Discovery 2003, 2, 205-213 10.1038/nrd1031
    • (2003) Nat. Rev. Drug Discovery , vol.2 , pp. 205-213
    • Jordan, V.C.1
  • 2
    • 85012009358 scopus 로고    scopus 로고
    • Estrogen receptors as therapeutic targets in breast cancer
    • Eckhard, O. Weinmann, H. Wiley-VCH Verlag GmbH: Weinheim, Germany
    • Ariazi, E. A.; Jordan, V. C. Estrogen receptors as therapeutic targets in breast cancer. In Nuclear Receptors as Drug Targets; Eckhard, O.; Weinmann, H.; Eds.; Wiley-VCH Verlag GmbH: Weinheim, Germany, 2008; pp 127-199.
    • (2008) Nuclear Receptors as Drug Targets , pp. 127-199
    • Ariazi, E.A.1    Jordan, V.C.2
  • 3
    • 0036998677 scopus 로고    scopus 로고
    • Fulvestrant ("Faslodex") - a new treatment option for patients progressing on prior endocrine therapy
    • Morris, C.; Wakeling, A. E. Fulvestrant ("Faslodex")-a new treatment option for patients progressing on prior endocrine therapy Endocr.-Relat. Cancer 2002, 9, 267-276 10.1677/erc.0.0090267
    • (2002) Endocr.-Relat. Cancer , vol.9 , pp. 267-276
    • Morris, C.1    Wakeling, A.E.2
  • 4
    • 33646930743 scopus 로고    scopus 로고
    • Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-α
    • Nephew, K. P.; Long, X. Fulvestrant (ICI 182,780)-dependent interacting proteins mediate immobilization and degradation of estrogen receptor-α J. Biol. Chem. 2006, 14, 9607-9615 10.1074/jbc.M510809200
    • (2006) J. Biol. Chem. , vol.14 , pp. 9607-9615
    • Nephew, K.P.1    Long, X.2
  • 6
    • 80051956348 scopus 로고    scopus 로고
    • Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer
    • Scott, S. M.; Brown, M.; Come, S. E. Emerging data on the efficacy and safety of fulvestrant, a unique antiestrogen therapy for advanced breast cancer Expert Opin. Drug Saf. 2011, 10, 819-826 10.1517/14740338.2011.595560
    • (2011) Expert Opin. Drug Saf. , vol.10 , pp. 819-826
    • Scott, S.M.1    Brown, M.2    Come, S.E.3
  • 7
    • 84931395503 scopus 로고    scopus 로고
    • Endocrine resistance: mechanisms and therapeutic targets
    • Damodaran, S.; Majumder, S.; Ramaswamy, B. Endocrine resistance: mechanisms and therapeutic targets Clin. Invest. 2013, 3, 681-690 10.4155/cli.13.49
    • (2013) Clin. Invest. , vol.3 , pp. 681-690
    • Damodaran, S.1    Majumder, S.2    Ramaswamy, B.3
  • 8
    • 84884559238 scopus 로고    scopus 로고
    • Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts
    • Li, S.; Shen, D.; Shao, J.; Crowder, R.; Liu, W.; Prat, A. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts Cell Rep. 2013, 4, 1116-30 10.1016/j.celrep.2013.08.022
    • (2013) Cell Rep. , vol.4 , pp. 1116-1130
    • Li, S.1    Shen, D.2    Shao, J.3    Crowder, R.4    Liu, W.5    Prat, A.6
  • 9
    • 84888391516 scopus 로고    scopus 로고
    • ESR1 ligand-binding domain mutations in hormone-resistant breast cancer
    • Toy, W.; Shen, Y.; Won, H.; Green, B.; Sakr, R. A.; Will, M. ESR1 ligand-binding domain mutations in hormone-resistant breast cancer Nat. Genet. 2013, 45, 1439-45 10.1038/ng.2822
    • (2013) Nat. Genet. , vol.45 , pp. 1439-1445
    • Toy, W.1    Shen, Y.2    Won, H.3    Green, B.4    Sakr, R.A.5    Will, M.6
  • 10
    • 1842633460 scopus 로고    scopus 로고
    • Fulvestrant: pharmacokinetics and pharmacology
    • Robertson, J. F. R.; Harrison, M. Fulvestrant: pharmacokinetics and pharmacology Br. J. Cancer 2004, 90 (Suppl. 1) S7-S10 10.1038/sj.bjc.6601630
    • (2004) Br. J. Cancer , vol.90 , pp. S7-S10
    • Robertson, J.F.R.1    Harrison, M.2
  • 11
    • 80052736785 scopus 로고    scopus 로고
    • Fulvestrant revisited: efficacy and safety of the 500-mg dose
    • Howell, A.; Sapunar, F. Fulvestrant revisited: efficacy and safety of the 500-mg dose Clin. Breast Cancer 2011, 11, 204-210 10.1016/j.clbc.2011.02.002
    • (2011) Clin. Breast Cancer , vol.11 , pp. 204-210
    • Howell, A.1    Sapunar, F.2
  • 12
    • 79958149945 scopus 로고    scopus 로고
    • The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy
    • Wardell, S. E.; Marks, J. R.; McDonnell, D. P. The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy Biochem. Pharmacol. 2011, 82, 122-130 10.1016/j.bcp.2011.03.031
    • (2011) Biochem. Pharmacol. , vol.82 , pp. 122-130
    • Wardell, S.E.1    Marks, J.R.2    McDonnell, D.P.3
  • 14
    • 0030741983 scopus 로고    scopus 로고
    • Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone
    • Willson, T. M.; Norris, J. D.; Wagner, B. L.; Asplin, I.; Baer, P.; Brown, H. R.; Jones, S. A.; Henke, B.; Sauls, H.; Wolfe, S.; Morris, D. C.; McDonnell, D. P. Dissection of the molecular mechanism of action of GW5638, a novel estrogen receptor ligand, provides insights into the role of estrogen receptor in bone Endocrinology 1997, 138, 3901-3911 10.1210/endo.138.9.5358
    • (1997) Endocrinology , vol.138 , pp. 3901-3911
    • Willson, T.M.1    Norris, J.D.2    Wagner, B.L.3    Asplin, I.4    Baer, P.5    Brown, H.R.6    Jones, S.A.7    Henke, B.8    Sauls, H.9    Wolfe, S.10    Morris, D.C.11    Mcdonnell, D.P.12
  • 15
    • 18944381947 scopus 로고    scopus 로고
    • Structural basis for an unexpected mode of SERM-mediated ER antagonism
    • Wu, Y.-L.; Yang, X.; Ren, Z.; McDonnell, D. P.; Norris, J. D.; Willson, T. M.; Greene, G. L. Structural basis for an unexpected mode of SERM-mediated ER antagonism Mol. Cell 2005, 18, 413-424 10.1016/j.molcel.2005.04.014
    • (2005) Mol. Cell , vol.18 , pp. 413-424
    • Wu, Y.-L.1    Yang, X.2    Ren, Z.3    McDonnell, D.P.4    Norris, J.D.5    Willson, T.M.6    Greene, G.L.7
  • 24
    • 0034989609 scopus 로고    scopus 로고
    • Understanding the genotoxicity of tamoxifen
    • Phillips, D. H. Understanding the genotoxicity of tamoxifen Carcinogenicity 2001, 22, 839-849 10.1093/carcin/22.6.839
    • (2001) Carcinogenicity , vol.22 , pp. 839-849
    • Phillips, D.H.1
  • 25
    • 84885524354 scopus 로고    scopus 로고
    • Selective estrogen receptor modulators
    • Fischer, J. Ganellin, C. R. Rotella, D. P. Wiley-VCH Verlag GmbH: Weinheim, Germany
    • Luniwal, A.; Jetson, R.; Erhardt, P. Selective estrogen receptor modulators. In Analogue-Based Drug Discovery III; Fischer, J.; Ganellin, C. R.; Rotella, D. P., Eds.; Wiley-VCH Verlag GmbH: Weinheim, Germany, 2013; pp 165-185.
    • (2013) Analogue-Based Drug Discovery III , pp. 165-185
    • Luniwal, A.1    Jetson, R.2    Erhardt, P.3
  • 26
    • 47249138273 scopus 로고    scopus 로고
    • Selective estrogen receptor modulator chemistry at Merck. A review
    • Blizzard, T. A. Selective estrogen receptor modulator chemistry at Merck. A review Curr. Top. Med. Chem. 2008, 8, 792-812 10.2174/156802608784535066
    • (2008) Curr. Top. Med. Chem. , vol.8 , pp. 792-812
    • Blizzard, T.A.1
  • 27
    • 79251504654 scopus 로고    scopus 로고
    • Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis
    • Gennari, L.; Merlotti, D.; Stolakis, K.; Nuti, R. Lasofoxifene, from the preclinical drug discovery to the treatment of postmenopausal osteoporosis Expert Opin. Drug Discovery 2011, 6 (2) 205-217 10.1517/17460441.2011.547188
    • (2011) Expert Opin. Drug Discovery , vol.6 , Issue.2 , pp. 205-217
    • Gennari, L.1    Merlotti, D.2    Stolakis, K.3    Nuti, R.4
  • 28
    • 4243241249 scopus 로고
    • The Pictet-Spengler condensation: a new direction for an old reaction
    • Cox, E. D.; Cook, J. M. The Pictet-Spengler condensation: a new direction for an old reaction Chem. Rev. 1995, 95, 1797-842 10.1021/cr00038a004
    • (1995) Chem. Rev. , vol.95 , pp. 1797-1842
    • Cox, E.D.1    Cook, J.M.2
  • 29
    • 77954068671 scopus 로고    scopus 로고
    • The asymmetric Pictet-Spengler reaction
    • Lorenz, M.; Van Linn, M. L.; Cook, J. M. The asymmetric Pictet-Spengler reaction Curr. Org. Synth. 2010, 7, 189-223 10.2174/157017910791163011
    • (2010) Curr. Org. Synth. , vol.7 , pp. 189-223
    • Lorenz, M.1    Van Linn, M.L.2    Cook, J.M.3
  • 30
    • 80052483777 scopus 로고    scopus 로고
    • The Pictet-Spengler Reaction in Nature and in Organic Chemistry
    • Stockigt, J.; Antonchick, A. P.; Wu, F.-R.; Waldmann, H. The Pictet-Spengler Reaction in Nature and in Organic Chemistry Angew. Chem., Int. Ed. 2011, 50, 8538-8564 10.1002/anie.201008071
    • (2011) Angew. Chem., Int. Ed. , vol.50 , pp. 8538-8564
    • Stockigt, J.1    Antonchick, A.P.2    Wu, F.-R.3    Waldmann, H.4
  • 31
    • 33646874831 scopus 로고    scopus 로고
    • A simple method for the synthesis of 1-substituted β-carboline derivatives from tryptamine and carboxylic acids in polyphosphoric acid
    • Ivanov, I.; Nikolova, S.; Statkova-Abeghe, S. A simple method for the synthesis of 1-substituted β-carboline derivatives from tryptamine and carboxylic acids in polyphosphoric acid Heterocycles 2005, 65, 2483-2492 10.3987/COM-05-10484
    • (2005) Heterocycles , vol.65 , pp. 2483-2492
    • Ivanov, I.1    Nikolova, S.2    Statkova-Abeghe, S.3
  • 32
    • 84931301519 scopus 로고    scopus 로고
    • A screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs)
    • Callis, R.; Rabow, A.; Tonge, M.; Bradbury, R.; Challinor, M.; Roberts, K.; Jones, K.; Walker, G. A screening Assay Cascade to Identify and Characterize Novel Selective Estrogen Receptor Downregulators (SERDs) J. Biomol. Screening 2015, 20, 748 10.1177/1087057115580298
    • (2015) J. Biomol. Screening , vol.20 , pp. 748
    • Callis, R.1    Rabow, A.2    Tonge, M.3    Bradbury, R.4    Challinor, M.5    Roberts, K.6    Jones, K.7    Walker, G.8
  • 35
    • 0141992796 scopus 로고    scopus 로고
    • The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione analogues
    • Daugan, A.; Grondin, P.; Ruault, C.; Le Monnier de Gouville, A.-C.; Coste, H.; Linget, J. M.; Kirilovsky, J.; Hyafil, F.; Labaudiniere, R. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1′,2′:1,6]pyrido[3,4-b]indole-1,4-dione analogues J. Med. Chem. 2003, 46, 4533-4542 10.1021/jm0300577
    • (2003) J. Med. Chem. , vol.46 , pp. 4533-4542
    • Daugan, A.1    Grondin, P.2    Ruault, C.3    Le Monnier De Gouville, A.-C.4    Coste, H.5    Linget, J.M.6    Kirilovsky, J.7    Hyafil, F.8    Labaudiniere, R.9
  • 37
    • 84945392145 scopus 로고    scopus 로고
    • http://www.clinicaltrials.gov/ct2/results?term=PTC299.
  • 40
    • 36749018204 scopus 로고    scopus 로고
    • Privileged structures: a useful concept for the rational design of new lead drug candidates
    • Duarte, C. D.; Barreiro, E. J.; Fraga, C. A. M. Privileged structures: a useful concept for the rational design of new lead drug candidates Mini-Rev. Med. Chem. 2007, 7, 1108-1119 10.2174/138955707782331722
    • (2007) Mini-Rev. Med. Chem. , vol.7 , pp. 1108-1119
    • Duarte, C.D.1    Barreiro, E.J.2    Fraga, C.A.M.3
  • 41
    • 84880147352 scopus 로고    scopus 로고
    • Privileged structures as leads in medicinal chemistry
    • Costantino, L.; Barlocco, D. Privileged structures as leads in medicinal chemistry Front. Med. Chem. 2010, 5, 381-422
    • (2010) Front. Med. Chem. , vol.5 , pp. 381-422
    • Costantino, L.1    Barlocco, D.2
  • 42
    • 35148869577 scopus 로고    scopus 로고
    • Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators
    • Wittmann, B. M.; Sherk, A.; McDonnell, D. P. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators Cancer Res. 2007, 67, 9549-9560 10.1158/0008-5472.CAN-07-1590
    • (2007) Cancer Res. , vol.67 , pp. 9549-9560
    • Wittmann, B.M.1    Sherk, A.2    McDonnell, D.P.3
  • 43
    • 78149501152 scopus 로고    scopus 로고
    • The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer
    • McDonnell, D. P.; Wardell, S. E. The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer Curr. Opin. Pharmacol. 2010, 10, 620-628 10.1016/j.coph.2010.09.007
    • (2010) Curr. Opin. Pharmacol. , vol.10 , pp. 620-628
    • McDonnell, D.P.1    Wardell, S.E.2
  • 44
    • 0023701360 scopus 로고
    • Novel antioestrogens without partial agonist activity
    • Wakeling, A. E.; Bowler, J. Novel antioestrogens without partial agonist activity J. Steroid Biochem. 1988, 31, 645-653 10.1016/0022-4731(88)90014-3
    • (1988) J. Steroid Biochem. , vol.31 , pp. 645-653
    • Wakeling, A.E.1    Bowler, J.2
  • 45
    • 0026395885 scopus 로고
    • A Potent Specific Pure Antiestrogen with Clinical Potential
    • Wakeling, A. E.; Dukes, M.; Bowler, J. A Potent Specific Pure Antiestrogen with Clinical Potential Cancer Res. 1991, 51, 3867-3873
    • (1991) Cancer Res. , vol.51 , pp. 3867-3873
    • Wakeling, A.E.1    Dukes, M.2    Bowler, J.3
  • 49
    • 34447337731 scopus 로고    scopus 로고
    • Prediction of human pharmacokinetics - gastrointestinal absorption
    • Fagerholm, U. Prediction of human pharmacokinetics-gastrointestinal absorption J. Pharm. Pharmacol. 2007, 59, 905-916 10.1211/jpp.59.7.0001
    • (2007) J. Pharm. Pharmacol. , vol.59 , pp. 905-916
    • Fagerholm, U.1
  • 50
    • 79953311521 scopus 로고    scopus 로고
    • A A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance
    • Miller, T. W.; Balko, J. M.; Ghazoui, Z.; Dunbier, A.; Anderson, H.; Dowsett, M. A A gene expression signature from human breast cancer cells with acquired hormone independence identifies MYC as a mediator of antiestrogen resistance Clin. Cancer Res. 2011, 17, 2024-2034 10.1158/1078-0432.CCR-10-2567
    • (2011) Clin. Cancer Res. , vol.17 , pp. 2024-2034
    • Miller, T.W.1    Balko, J.M.2    Ghazoui, Z.3    Dunbier, A.4    Anderson, H.5    Dowsett, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.